{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:03:42Z","timestamp":1790730222172,"version":"4.1.0"},"reference-count":42,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["MA1648\/12-2"],"award-info":[{"award-number":["MA1648\/12-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Artemisone is an innovative artemisinin derivative with applications in the treatment of malaria, schistosomiasis and other diseases. However, its low aqueous solubility and tendency to degrade after solubilisation limits the translation of this drug into clinical practice. We developed a self-microemulsifying drug delivery system (SMEDDS), which is easy to produce (simple mixing) with a high drug load. In addition to known pharmaceutical excipients (Capmul MCM, Kolliphor HS15, propylene glycol), we identified Polysorb ID 46 as a beneficial new additional excipient. The physicochemical properties were characterized by dynamic light scattering, conductivity measurements, rheology and electron microscopy. High storage stability, even at 30 \u00b0C, was achieved. The orally administrated artemisone SMEDDS formulation was highly active in vivo in S. mansoni infected mice. Thorough elimination of the adult worms, their eggs and prevention of the deleterious granuloma formation in the livers of infected mice was observed even at a relatively low dose of the drug. The new formulation has a high potential to accelerate the clinical use of artemisone in schistosomiasis and malaria.<\/jats:p>","DOI":"10.3390\/pharmaceutics12060509","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T04:36:09Z","timestamp":1591245369000},"page":"509","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Oral Administration of Artemisone for the Treatment of Schistosomiasis: Formulation Challenges and In Vivo Efficacy"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-7800","authenticated-orcid":false,"given":"Johanna","family":"Zech","sequence":"first","affiliation":[{"name":"Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Kurt-Mothes-Str. 3, 06120 Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gold","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeen","family":"Salaymeh","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Molecular Genetics, The Kuvin Centre for the Study of Infectious and Tropical Diseases, The Hebrew University of Jerusalem, Jerusalem 9112002, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Netanel Cohen","family":"Sasson","sequence":"additional","affiliation":[{"name":"Department of Medical Neurobiology, Institute for Medical Research-Israel-Canada, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112002, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0361-9055","authenticated-orcid":false,"given":"Ithai","family":"Rabinowitch","sequence":"additional","affiliation":[{"name":"Department of Medical Neurobiology, Institute for Medical Research-Israel-Canada, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112002, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Golenser","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Molecular Genetics, The Kuvin Centre for the Study of Infectious and Tropical Diseases, The Hebrew University of Jerusalem, Jerusalem 9112002, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1613-6976","authenticated-orcid":false,"given":"Karsten","family":"M\u00e4der","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Kurt-Mothes-Str. 3, 06120 Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"Schistosomiasis-from immunopathology to vaccines","volume":"19","author":"McManus","year":"2020","journal-title":"Semin. Immunopathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1016\/j.bmc.2017.04.031","article-title":"Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine","volume":"25","author":"Campos","year":"2017","journal-title":"Bioorganic Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/0929867325666180926145537","article-title":"The Mechanism of Action of Praziquantel: Can New Drugs Exploit Similar Mechanisms?","volume":"27","author":"Thomas","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/bs.armc.2019.06.002","article-title":"Dealing with schistosomiasis: Current drug discovery strategies","volume":"Volume 53","author":"Gemma","year":"2019","journal-title":"Annual Reports in Medicinal Chemistry"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijpddr.2017.05.002","article-title":"Elimination of Schistosoma mansoni in infected mice by slow release of artemisone","volume":"7","author":"Gold","year":"2017","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02582-16","article-title":"Praziquantel for schistosomiasis: Single-drug metabolism revisited, mode of action, and resistance","volume":"61","author":"Vale","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bergquist, R., and Elmorshedy, H. (2018). Artemether and Praziquantel: Origin, Mode of Action, Impact, and Suggested Application for Effective Control of Human Schistosomiasis. Trop. Med. Infect. Dis., 125.","DOI":"10.3390\/tropicalmed3040125"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.phrs.2016.02.017","article-title":"Antischistosomal activity of artemisinin derivatives in vivo and in patients","volume":"110","author":"Saeed","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1179\/000349804225003460","article-title":"Efficacy of artesunate in the treatment of urinary schistosomiasis, in an endemic community in Nigeria","volume":"98","author":"Ejezie","year":"2004","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"ref_10","first-page":"193","article-title":"Evaluation of artesunate and praziquantel combination therapy in murine schistosomiasis mansoni","volume":"13","author":"Hegazy","year":"2018","journal-title":"Iran. J. Parasitol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"P\u00e9rez del Villar, L., Burguillo, F.J., L\u00f3pez-Ab\u00e1n, J., and Muro, A. (2012). Systematic Review and Meta-Analysis of Artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0045867"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00436-018-6188-9","article-title":"In vitro and in vivo evaluation of six artemisinin derivatives against Schistosoma mansoni","volume":"118","author":"Mendes","year":"2019","journal-title":"Parasitol. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/anie.200503071","article-title":"Artemisone-A highly active antimalarial drug of the artemisinin class","volume":"45","author":"Haynes","year":"2006","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.nano.2015.07.010","article-title":"In vitro anti-cancer effects of artemisone nano-vesicular formulations on melanoma cells","volume":"11","author":"Dwivedi","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.vetpar.2016.01.013","article-title":"Neospora caninum: Chronic and congenital infection in consecutive pregnancies of mice","volume":"219","author":"Mazuz","year":"2016","journal-title":"Vet. Parasitol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"104639","DOI":"10.1016\/j.antiviral.2019.104639","article-title":"Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus","volume":"172","author":"Laskov","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijpharm.2011.05.003","article-title":"Absorption of the novel artemisinin derivatives artemisone and artemiside: Potential application of PheroidTM technology","volume":"414","author":"Steyn","year":"2011","journal-title":"Int. J. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.bcp.2008.10.015","article-title":"Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparum malaria parasites is endoperoxide-dependent","volume":"77","author":"Hartwig","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11095-018-2471-9","article-title":"Formulation of Natural Oil Nano-Emulsions for the Topical Delivery of Clofazimine, Artemisone and Decoquinate","volume":"35","author":"Burger","year":"2018","journal-title":"Pharm. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1208\/s12249-018-1251-5","article-title":"Topical Delivery of Artemisone, Clofazimine and Decoquinate Encapsulated in Vesicles and Their In vitro Efficacy Against Mycobacterium tuberculosis","volume":"20","author":"Viljoen","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"ref_21","unstructured":"Zech, J., Timoracky, M., Syrowatka, F., and M\u00e4der, K. (2018, January 19\u201322). Artemisone in Electrosprayed Solid Lipid Microparticles. Proceedings of the PBP World Meeting, Granada, Spain."},{"key":"ref_22","first-page":"2016","article-title":"New isosorbide derivates for drug solubilization","volume":"8","author":"Palmieri","year":"2016","journal-title":"Roquette Fr\u00e8res"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11959","DOI":"10.1039\/C5RA27537G","article-title":"Synthesis of biosafe isosorbide dicaprylate ester plasticizer by lipase in a solvent-free system and its sub-chronic toxicity in mice","volume":"6","author":"Cui","year":"2016","journal-title":"RSC Adv."},{"key":"ref_24","unstructured":"(2020, April 01). Isosorbide Diesters-Brief Profile-ECHA. Available online: https:\/\/echa.europa.eu\/brief-profile\/-\/briefprofile\/100.121.882."},{"key":"ref_25","unstructured":"International Conference on Harmonisation ICH (1997). Q2(R1): Validation of analytical procedures: Text and methodology. Fed. Regist., 62, 27463\u201327467."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ejps.2008.09.006","article-title":"A new self-emulsifying drug delivery system (SEDDS) for poorly soluble drugs: Characterization, dissolution, in vitro digestion and incorporation into solid pellets","volume":"35","author":"Abdalla","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_27","unstructured":"BASF (2020, May 31). Kolliphor\u00ae HS 15. Available online: https:\/\/pharmaceutical.basf.com\/global\/en\/drug-formulation\/products\/kolliphor-hs-15.html."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ijpharm.2005.04.016","article-title":"A lecithin-based microemulsion of rh-insulin with aprotinin for oral administration: Investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats","volume":"298","author":"Tirnaksiz","year":"2005","journal-title":"Int. J. Pharm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.addr.2012.09.018","article-title":"Microemulsion-based media as novel drug delivery systems","volume":"64","author":"Lawrence","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_30","first-page":"105","article-title":"Inflammation in schistosomiasis","volume":"17","author":"Bloch","year":"1979","journal-title":"Bibl. Anat."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.3389\/fimmu.2018.03042","article-title":"Schistosome Egg Migration: Mechanisms, Pathogenesis and Host Immune Responses","volume":"9","author":"Costain","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/10408441003610571","article-title":"Toxicity of the antimalarial artemisinin and its dervatives","volume":"40","author":"Efferth","year":"2010","journal-title":"Crit. Rev. Toxicol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.toxlet.2003.12.009","article-title":"Artemisinin derivatives: Toxic for laboratory animals, safe for humans?","volume":"147","author":"Gordi","year":"2004","journal-title":"Toxicol. Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1128\/AAC.01553-13","article-title":"Treatment of murine cerebral malaria by artemisone in combination with conventional antimalarial drugs: Antiplasmodial effects and immune responses","volume":"58","author":"Guiguemde","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.reprotox.2016.08.003","article-title":"Clinical and non-clinical safety of artemisinin derivatives in pregnancy","volume":"65","author":"Gomes","year":"2016","journal-title":"Reprod. Toxicol."},{"key":"ref_36","unstructured":"Maronpot, R.R. (2020, April 01). Liver\u2013Inflammation, Available online: https:\/\/ntp.niehs.nih.gov\/nnl\/hepatobiliary\/liver\/inflamm\/index.htm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0003593","article-title":"Drug-Induced Exposure of Schistosoma mansoni Antigens SmCD59a and SmKK7","volume":"9","author":"Reimers","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13071-018-3132-x","article-title":"Assessment of tegumental damage to Schistosoma mansoni and S. haematobium after in vitro exposure to ferrocenyl, ruthenocenyl and benzyl derivatives of oxamniquine using scanning electron microscopy","volume":"11","author":"Buchter","year":"2018","journal-title":"Parasites Vectors"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.resinv.2018.12.003","article-title":"Leukotrienes: One step in our understanding of asthma","volume":"57","author":"Sirois","year":"2019","journal-title":"Respir. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-018-0013-8","article-title":"Schistosomiasis","volume":"4","author":"McManus","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40249-017-0286-2","article-title":"Controlling schistosomiasis with praziquantel: How much longer without a viable alternative?","volume":"6","author":"Bergquist","year":"2017","journal-title":"Infect. Dis. Poverty"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/6\/509\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:35:11Z","timestamp":1760175311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/6\/509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["pharmaceutics12060509"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics12060509","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]}}}